5 Best Peptides for OCD

What to Know Before Choosing a Peptide for OCD

OCD is not a simple anxiety disorder that a single compound can reliably quiet. It is a condition rooted in specific dysfunction in the brain's cortico-striato-thalamo-cortical circuit, a loop connecting the orbitofrontal cortex, the striatum, the globus pallidus, and the thalamus that becomes locked in a cycle of excitation without adequate inhibition. The primary drivers of that dysfunction are glutamate hyperactivity on the excitatory side and serotonin insufficiency on the inhibitory side. The treatments with the most robust evidence, SSRIs and a form of psychotherapy called Exposure and Response Prevention, work directly on those systems. No peptide currently approved anywhere in the world works the same way.

That context matters for how to read this list. The compounds here were included because people are using them, discussing using them, or being prescribed them off-label in connection with OCD or OCD-adjacent symptoms. That is the inclusion criterion: real-world use and active discussion, not FDA approval and not the depth of the clinical trial record. A compound that exists only in community protocols belongs here just as much as one with published research behind it, and each compound's evidence is described as honestly as the strongest entry on the list. You will not find every entry claiming robust randomized controlled trial data, because that data does not exist for any peptide in OCD. What you will find is a straight account of what each compound is, why it is being discussed for OCD, and where the evidence actually stands.

The entries are numbered by how prominently each compound appears in research and documented real-world use, not as a ranking from best to worst. The right compound for any individual depends on far more than a numbered list can capture: symptom profile, current medications, history, and risk tolerance all factor in. The numbers give the list a logical shape. They are not a recommendation.

1. Selank: For the Anxiety and Emotional Regulation Component

Selank is a synthetic heptapeptide developed in Russia, built from a fragment of the naturally occurring immunomodulatory peptide tuftsin. It reached the public conversation primarily through its anxiolytic profile, meaning its studied ability to reduce anxiety, and that is the reason it leads most discussions about peptides and OCD. Anxiety is not the same as OCD, but the two are deeply intertwined: the intrusive thoughts and compulsive rituals of OCD are maintained partly by anxiety, and the hyperactivated circuit that drives OCD is fed by the same emotional dysregulation systems that Selank is thought to modulate.

The mechanism is worth understanding in plain terms. Selank appears to increase levels of leu-enkephalin, a naturally occurring opioid peptide that the brain produces to modulate pain and anxiety signals. Research into OCD neurobiology has proposed that the opioid system may contribute to the characteristic self-doubt loop of the condition, the inability to feel certain enough to stop checking, recounting, or repeating. Whether Selank's effect on leu-enkephalin meaningfully interrupts that loop in people with OCD is not established. What the Russian research does support is Selank's broader anxiolytic effect, real and observed in controlled settings, though studied primarily for generalized anxiety rather than OCD specifically. Beyond the opioid pathway, Selank is thought to modulate serotonin and glutamate transmission to some degree, both of which are central to OCD pathophysiology, but this mechanistic overlap has not been translated into OCD-specific clinical trials.

No published Phase 3 randomized controlled trials in Western medical literature have studied Selank as a treatment for OCD. The Russian research base supports its anxiolytic and broadly neuroprotective properties. Some psychiatrists use it off-label in clinical settings, delivered intranasally, as an adjunct to existing psychiatric care rather than a replacement for SSRIs or therapy. What is largely absent is any head-to-head trial against standard OCD treatments, any longitudinal safety data for psychiatric use, and any OCD-specific outcome measurement. The evidence here is clinical inference and off-label practitioner experience, not controlled OCD trial data.

Selank is delivered primarily via nasal spray. Intranasal delivery introduces a practical variable: absorption through this route can be less consistent than subcutaneous injection, which means the effect any individual experiences may vary from one use to the next. In the United States, Selank is available as a research compound rather than a pharmaceutical product. That carries the sourcing risks common to unregulated gray-market peptides: no FDA quality oversight, variable purity, and no standardized dosing protocol established for OCD.

2. Semax: For Cognitive Rigidity and Stress-Linked Symptoms

Semax is a synthetic peptide of Russian origin, derived from a fragment of adrenocorticotropic hormone. Where Selank's primary story is anxiolytic, Semax's centers on cognitive support and neuroplasticity, and those qualities are why it appears alongside Selank in most discussions about peptides and mental health. The two are often described as a complementary pairing: Selank for the emotional and anxiety component, Semax for the cognitive and stress-response side.

The mechanism most relevant to OCD is Semax's effect on brain-derived neurotrophic factor, commonly called BDNF. Think of BDNF as a fertilizer for neurons: it supports the survival of existing brain cells and encourages the formation of new connections, and it plays a meaningful role in cognitive flexibility, the capacity to shift out of a looping pattern of thought or behavior and redirect attention. One of the defining features of OCD is a failure of exactly that flexibility. Animal research and some human neurological studies suggest Semax reliably increases BDNF expression, though whether that increase translates to improved cognitive flexibility in OCD specifically is a question no published trial has yet answered.

Semax also appears to influence the corticotropin-releasing factor system, the pathway that connects stress exposure to hormonal and behavioral responses. Stress is a well-established trigger for OCD symptom exacerbation: when the stress response is overactive, the brain's obsessive loops tend to tighten. A compound that moderates the stress response downstream might reduce the frequency or intensity of OCD episodes without addressing their root cause directly. This indirect-benefit model is the basis for how Semax is discussed in OCD-adjacent communities.

No human clinical trial has been published studying Semax as a treatment for OCD as of 2026. The available research comes from Russian studies on neurological health, stress resilience, and BDNF modulation, none conducted with OCD as the primary outcome measure. Community use of Semax for OCD is not extensively catalogued; it appears more frequently in general nootropic and mental health discussions than in OCD-specific spaces. Its use in this context is largely inferential, built on the reasonable logic that a compound supporting cognitive flexibility and stress reduction might help with a disorder characterized by cognitive rigidity and stress-triggered symptom spikes. That inference is worth naming honestly rather than presenting it as established efficacy.

Semax is available as a research compound in the United States, with no standardized pharmaceutical formulation and no FDA approval for any psychiatric indication.

3. GLP-1 Receptor Agonists: For Compulsive Behavior Patterns

The GLP-1 receptor agonists, with semaglutide and tirzepatide being the two most discussed, sit in a different category from Selank and Semax. They are FDA-approved peptide-based medications developed for type 2 diabetes and weight management, and they entered the OCD conversation not through a formal research agenda but through a pattern of user-reported observations substantial enough to warrant honest coverage.

The reports cluster around a specific symptom type: body-focused repetitive behaviors and compulsive checking. Users taking tirzepatide for weight management have reported reductions in skin picking and nail picking that they describe as dramatic, with some accounts noting very substantial decreases in those behaviors. Semaglutide reports are more mixed, with some users noting reduced nail biting and hair pulling including observations from their own therapists, while others on the medication for extended periods describe no meaningful OCD benefit. Across these accounts, one pattern appears consistently: the effects reverse when the medication is stopped. That reversal tells you something important about mechanism. These are not permanent neurological changes but ongoing pharmacological effects that end when the drug leaves the system.

The proposed connection runs through the reward and satiety circuitry that GLP-1 receptors influence in the brain. Dopamine signaling in the striatum, the same region implicated in the CSTC circuit dysfunction of OCD, is modulated by GLP-1 receptor activity. Whether this represents a genuine pathway for treating OCD symptoms or a secondary effect of broader reward-system quieting is an open question that no peer-reviewed study has formally tested in an OCD population.

The critical limitation is real and matters: no longitudinal peer-reviewed studies support GLP-1 agonists as treatments for core OCD symptoms, meaning intrusive thoughts and primary compulsions. The community-reported benefits appear strongest for body-focused repetitive behaviors and compulsive eating patterns, which overlap with OCD phenomenology but are not the same as classical OCD. For those specific subtypes, the signal in user reports is interesting and worth following as research develops. For OCD more broadly, the evidence remains anecdotal and the mechanism indirect. Anyone currently on an SSRI or other psychiatric medication would also need to consider unknown interaction risks before pursuing that combination.

4. Cerebrolysin: For Neuroprotection and Cognitive Support

Cerebrolysin is a preparation of low-molecular-weight neuropeptides and amino acids derived from porcine brain tissue. It is not a single peptide but a peptide mixture, and its established clinical use sits in neurological rather than psychiatric contexts. It holds approval in several European and Asian countries for conditions including stroke rehabilitation, vascular dementia, and traumatic brain injury, where neuroprotection is the primary rationale.

Its connection to OCD is indirect and conceptual. OCD involves dysfunction in neural circuits that depend on healthy neuronal communication and structural integrity. Cerebrolysin's proposed mechanisms include promoting neuronal survival, supporting synaptic plasticity, and reducing inflammatory processes in neural tissue. Think of it as maintenance support for the circuitry rather than a direct intervention on any single neurotransmitter system. The argument for its use in OCD follows the same reasoning as Semax: if the circuitry underlying OCD is functionally impaired, a compound supporting circuit integrity might reduce symptom severity over time.

No completed randomized controlled trial has studied Cerebrolysin specifically for OCD. The neuroprotective evidence base, while genuine and reasonably robust for stroke and dementia applications, has not been directed at OCD pathophysiology in any systematic way. Cerebrolysin surfaces in OCD discussions primarily in the context of treatment-refractory presentations, people who have already worked through established options without sufficient relief and are exploring adjunctive approaches. That use is experiential rather than clinical, and the evidence is drawn from neuroprotective research in other conditions rather than OCD outcomes. Cerebrolysin is not FDA-approved for any indication in the United States and is accessed primarily through international sourcing channels where it holds approval.

5. Bremelanotide: For Investigational Behavioral Regulation

Bremelanotide, known in peptide communities by the research designation PT-141, is a synthetic melanocortin receptor agonist. It carries FDA approval for hypoactive sexual desire disorder in premenopausal women, and that is the clinical context it is known for. Its presence in OCD discussions is more peripheral and more speculative than any other compound on this list, included here because it does appear in that conversation and the inclusion criterion is real-world discussion, not established use.

The proposed connection runs through the melanocortin system, the receptor network that bremelanotide acts on. Melanocortin receptors are expressed in brain regions that overlap with OCD-relevant circuitry, including the striatum and prefrontal cortex. Preclinical research has explored whether melanocortin signaling influences stereotyped and compulsive behaviors in animal models, and those findings are what brings bremelanotide into OCD conversations. The animal model data is hypothesis-generating rather than conclusive, and the mechanistic link to the specific CSTC circuit dysfunction that drives OCD remains indirect.

No human clinical trial data supports the use of bremelanotide for OCD as of 2026. Community use for OCD is sparse, appearing in occasional discussions rather than as any consistent pattern of adoption. Its inclusion here reflects its status as a recurring investigational mention rather than a compound with established real-world use for this goal. Anyone considering it would be doing so entirely outside any established clinical framework, with no OCD-specific safety data, no OCD-specific dosing guidance, and no human trial evidence to draw on.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for OCD?

No peptide is currently FDA-approved for the treatment of OCD. The FDA has approved roughly ten therapeutic peptide drugs in total, covering conditions such as diabetes, sexual dysfunction, and weight management, but none of those approvals extend to OCD. All of the compounds in this guide are being used or discussed for OCD in an off-label or research context.

How do these peptides relate to standard OCD treatments?

Standard OCD treatment involves SSRIs such as sertraline and fluoxetine, sometimes combined with the tricyclic antidepressant clomipramine, alongside a psychotherapy approach called Exposure and Response Prevention. None of the peptides on this list replaces those treatments or has been studied head-to-head against them for OCD outcomes. Where peptides appear in clinical settings for OCD-adjacent symptoms, they are used as adjuncts, meaning additions to an existing treatment plan rather than substitutes for it.

Is there a meaningful difference between using these compounds for anxiety versus OCD?

Yes, and it matters practically. Anxiety and OCD share features, and anxiety is a component of OCD, but OCD involves a specific kind of circuit-level dysfunction that anxiety treatments do not always address directly. Selank's evidence base, for example, is built on anxiety outcomes rather than OCD outcomes, so applying it to OCD is an extrapolation from a related but distinct condition. That does not make it irrelevant to OCD, but it does mean the evidence picture is thinner than the anxiety literature alone might suggest.

What are the main risks of using research-grade peptides for OCD?

Research-grade peptides sold outside a pharmaceutical framework carry risks that prescription medications do not: variable purity, inconsistent potency, and no quality oversight. For anyone already on psychiatric medications, there is also the question of unknown interaction risks, since no systematic study has tested these combinations in OCD populations. Intranasal delivery, used for both Selank and Semax, can produce variable absorption, making consistent effects harder to predict. Anyone considering these compounds alongside existing OCD treatment should discuss them with a prescribing clinician first.

Why do some GLP-1 users report OCD improvement when the mechanism does not directly target OCD?

The leading explanation is that GLP-1 receptor agonists influence the brain's dopamine and reward circuitry broadly, and that influence has downstream effects on repetitive and compulsive behavior patterns that share circuitry with OCD. Body-focused repetitive behaviors in particular may respond to reward-system modulation even without any direct action on the serotonin and glutamate pathways that drive classical OCD. The fact that these effects reverse quickly when the medication is stopped supports the view that this is an ongoing pharmacological effect rather than a lasting change to underlying OCD circuitry.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for OCD in one place.